Site Search

>> Advanced Search

Free Newsletter

  Email address:
   

>> Preview...
In the News
Greg Scott presents industry update during JPMorgan
>> View video…

>> More News...

Now on Twitter!
 

Twitter ID: ChinaBio

D-Pharm Outlicenses Stroke Drug to Wanbang Biopharma

publication date: Nov 9, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

D-Pharm Ltd. of Israel has outlicensed the China rights to its treatment for ischemic stroke to Wanbang Biopharmaceuticals Ltd. The drug, DP-b99, is currently in a Phase III multi-national clinical trial. D-Pharm and Wanbang will co-develop DP-b99 in China, with Wanbang underwriting the cost for the first 450 China patients in a Phase III trial. D-Pharm will be responsible for any additional patients. More details...

Stock Symbol: (TASE: DPRM)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events
April 14, 2010
Guangzhou, China

SEED Final Competion and Award Ceremony
April 23, 2010
Shanghai, China
Suzhou, China
June 23-24, 2010
 
Partner Events

China 2010 Pharmaceutical R&D Summit
Shanghai, China
April 5-8, 2010
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners